Conference call today at 9:00 am ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "MannKind closed 2025 with strong momentum across our commercial portfol ...

Exhibit 99.1 Rackspace Technology Reports Fourth Quarter and Full Year 2025 Results SAN ANTONIO, February 26, 2026 – Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end hybrid cloud and AI solutions company, today announced results for its fourth quarter and year ended December 31, 2025. Gajen Kandiah, Chief Executive Officer, stated, "Q4 capped a year of meaningful progress and marks a clear inflection point for Rackspace. We made the structural decisions that position us to win — a sharpened fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39511 ___________________________ BURFORD CAPITAL LIMITED (Exa ...

Exhibit 99.1 – CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 – – Phase 1 healthy adult trial data of EDG-15400 and plans for heart failure studies expected in H1 2026 – – Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy (Becker) expected in Q4 2026 – News Release Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascula ...

Exhibit 99.1 Playtika Holding Corp. Reports Q4 and 2025 Financial Results Revenue of $678.8 million and Direct-to-Consumer ("DTC") Revenue of $250.1 million DTC Revenue Increased 19.5% Sequentially and 43.2% Year-Over-Year Net Loss of $(309.3) million, Adjusted Net Income of $89.0 million, and Adjusted EBITDA of $201.4 million Herzliya, Israel – February 26, 2026 - Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its fourth quarter and fiscal year ended December 31, 2025. Fourth Qu ...

Atlanta, Georgia – February 26, 2026. . . Gray Media (NYSE: GTN) today announced its financial results for the fourth quarter that ended December 31, 2025. EXECUTIVE COMMENTARY Hilton Howell, Jr., Chairman and CEO, commented, "We delivered strong fourth quarter financial results, with revenue and Adjusted EBITDA exceeding consensus expectations. The quarter benefited from better-than-expected MVPD subscriber trends, which drove year-over-year growth in "Net Retransmission Revenue" (retransmission consent re ...

Exhibit 99.1 Gray Media Reports Fourth Quarter Results Exceeding Guidance Atlanta, Georgia – February 26, 2026. . . Gray Media (NYSE: GTN) today announced its financial results for the fourth quarter that ended December 31, 2025. EXECUTIVE COMMENTARY Hilton Howell, Jr., Chairman and CEO, commented, "We delivered strong fourth quarter financial results, with revenue and Adjusted EBITDA exceeding consensus expectations. The quarter benefited from better-than-expected MVPD subscriber trends, which drove year-o ...

Exhibit 99.1 Financial Guidance for 2026 CARY, N.C., February 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron's Acute Care franc ...

Burford Burford Capital Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 This presentation is for the use of Burford's public shareholders and is not an offering of any Burford private fund. Notice and disclaimer This presentation (this "Presentation") provides certain information to facilitate review and understanding of the business, financial condition and results of operations of Burford Capital Limited (together with its subsidiaries, the "Company", "Burford", " we", " our" or "us" ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | --- | ...